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SUMMARY
Percutaneous testicular sperm aspiration (TESA) has been known for decades as a simple, minimally invasive approach to sperm
retrieval in azoospermic men. Because of lower reported sperm retrieval rates (SRR) when compared with microdissection testicular
sperm extraction (mTESE), many centers now use mTESE as the first choice for retrieving spermatozoa in nonobstructive azoosper-
mia (NOA). Objectives of this study were to evaluate the outcome and safety of TESA and mTESE in the treatment of azoospermia
and to investigate the usefulness of a prognostic TESA to individualize protocols for couples and limit the use of invasive testicular
procedures. IRB approval was obtained to retrospectively evaluate 208 patients undergoing multiple needle-pass TESA between 1999
and 2014. Prognostic TESA was performed on 125 men with NOA and 82 with obstructive azoospermia (OA). Nine NOA men and 31
OA men with previously demonstrated spermatozoa had a subsequent therapeutic TESA while nine NOA men with a failed TESA pro-
ceeded to mTESE. Main outcome measures were complication rates and SRR. SRR of the prognostic TESA was 30% (38/125) for NOA
men and 100% (82/82) for OA men. Eight/nine NOA men and 31/31 OA men had spermatozoa found for intracytoplasmic sperm
injection in a subsequent therapeutic TESA. In nine NOA men in whom a TESA produced no spermatozoa, only one had spermato-
zoa found with mTESE. Overall complication rates of TESA and mTESE were 3% (7/267) and 21% (3/14), respectively. TESA provides
reasonable SRR and is a safe procedure. Successful prognostic TESA indicates future success with therapeutic TESA. Men with a
failed TESA have a limited chance of sperm retrieval using mTESE. Approaching azoospermic men with an initial prognostic TESA
followed by either therapeutic TESA and/or mTESE is an efficient algorithm in the management of azoospermia and limits the use of
more invasive procedures.
INTRODUCTION
Azoospermia is defined as the absence of spermatozoa in the
ejaculate verified in at least two samples, including assessment
of the centrifuged pellet (WHO 5th edition). The condition is
observed in 1% of the general population and affects 10–15% of
infertile men (Willott, 1982; Jarow et al., 1989; Gudeloglu &
Parekattil, 2013). Azoospermia is divided into obstructive
azoospermia (OA) and nonobstructive azoospermia (NOA), of
which the latter constitutes 60% (Willott, 1982; Jarow et al., 1989;
Gudeloglu & Parekattil, 2013).
In OA one can attempt reconstructive surgery of the efferent
ducts to allow spermatozoa to reach the ejaculate (Wosnitzer &
Goldstein, 2014). In non-reconstructible cases it is relatively sim-
ple to obtain spermatozoa from the testis or epididymis and the
outcomes of the available surgical methods seem to be similar
(Wald et al., 2007). This is not the case in NOA where sperm
production is either absent or markedly reduced. In NOA
patients the focus has been on percutaneous testicular sperm
aspiration (TESA), conventional open testicular sperm extraction
(cTESE), and microdissection testicular sperm extraction
(mTESE). However, no consensus on a sperm retrieval protocol
for these men has been reached.
TESA is a minimally invasive option in which a biopsy needle
is used to aspirate testicular tissue, usually under local anesthe-
sia in a clinic setting. Meanwhile, cTESE is a more invasive open
procedure, with the risk of complications in the form of testicu-
lar vessel damage (Schlegel, 2009). The more complex mTESE is
also an open procedure but the risk of complications is reduced
as less tissue is removed (Amer et al., 2000; Okada et al., 2002;
Ramasamy et al., 2005). Overall sperm retrieval rates (SRR) for
TESA, cTESE, and mTESE are usually reported around 25%, 49%,
and 52%, respectively, but significant variations exist (Donoso
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et al., 2007; Dabaja & Schlegel, 2013; Deruyver et al., 2014).
These variations become apparent in studies comparing TESA
and cTESE where SRR ranges from 11 to 60% in TESA and 43–
72% in cTESE (Friedler et al., 1997; Ezeh et al., 1998; Rosenlund
et al., 1998; Khadra et al., 2003; Hauser et al., 2006; Houwen
et al., 2008). In studies comparing cTESE and mTESE, SRR
ranges from 17 to 45% in cTESE and 43–63% in mTESE (Schlegel,
1999; Amer et al., 2000; Okada et al., 2002; Tsujimura et al.,
2002; Ramasamy et al., 2005; Turunc et al., 2010; Ghalayini
et al., 2011). However, although mTESE provides better SRR
potential disadvantages include higher cost, longer procedure
time, and use of general anesthesia.
Since 1999 we have approached NOA men and azoospermic
men where clinical evidence was not completely indicative of
either OA or NOA with an initial prognostic TESA in the clinic,
and if favorable testing results are seen, we use the same sperm
retrieval procedure for subsequent in vitro fertilization (IVF). If
either the prognostic- or the therapeutic TESA fail, we offer
mTESE. This protocol was established to individualize sperm
retrieval for IVF to minimize cost and invasiveness.
The purpose of this study was to retrospectively evaluate this
approach. To do so, we describe success rate after prognostic
TESA, concordance of prognostic and therapeutic TESA results,
success rate of mTESE after failed TESA and complication rates
from the two procedures. Furthermore, we describe the effects
of the surgical procedures on follicle-stimulating hormone (FSH)
and testosterone and the relation between SRR and a number of
clinical parameters.
MATERIALS ANDMETHODS
Patients
We reviewed records of azoospermic patients who underwent
TESA at Briarwood Center for Reproductive Medicine, University
of Michigan between April 1999 and January 2014.
In patients with normal ejaculation, azoospermia was con-
firmed in at least two semen analyses (SA). In patients with ane-
jaculation, azoospermia was diagnosed on a SA obtained
through either penile vibratory stimulation or electroejaculation
when possible. If it was not possible to obtain a SA, patients were
considered azoospermic by definition.
The diagnosis of OA/NOA was determined by the same experi-
enced andrologist based on a full medical history, physical
examination, hormonal evaluation, karyotype, Y chromosome
microdeletion testing, and histopathological diagnosis. The gen-
eral criteria for NOA were a combination of at least two of the
following: testes <4 cm in length, follicle-stimulating hormone
(FSH) ≥10 mIU/mL, and histology showing hypospermatogene-
sis (HS), maturation arrest (MA), or Sertoli cell-only syndrome
(SCOS). The definition used for HS was all stages of spermatoge-
nesis seen, but markedly decreased numbers of mature sper-
matids. Patients with AZF deletions, SCOS, or MA were grouped
as NOA without regard to other criteria. If azoospermic patients
did not fit our diagnostic requirements for NOA, they were
grouped as OA.
Treatable causes of azoospermia were investigated and treat-
ment initiated when deemed appropriate, before attempting
sperm retrieval. Patients were excluded from the study when
such treatments were successful.
Treatment algorithm
As described above, an initial prognostic TESA was performed
in NOA men and azoospermic men where clinical evidence was
not completely indicative of either OA or NOA. If the prognostic
TESA was successful the procedure was repeated in future IVF
cycles. If the prognostic TESA or the therapeutic TESA failed
mTESE was offered to retrieve spermatozoa (Fig. 1a). Both TESA
and mTESE were deemed successful if at least one spermato-
zoon was retrieved. All repeat procedures were separated by a
time interval of at least 2 months (usually 6 months) to allow
recovery of the testicular tissue.
TESA procedure
The patient’s scrotum is prepped with alcohol and draped. A
spermatic cord block with 0.5% bupivacaine is instilled and a
small skin wheal raised overlying the testis.
An 18 gauge needle is then introduced into each testis, and
negative pressure applied with a 10 mL syringe. Multiple passes
throughout the entire testis, numbering 50–100 passes, are made
through a single percutaneous/tunical entry and continued until
tissue is visible in the hub of the needle. This is removed by brisk
extraction of the needle and pressure held to tamponade bleed-
ing. The specimen is split and sent for standard histology in
Bouin’s solution, and in media for live sperm analysis by the
assisted reproductive technology (ART) laboratory.
The tissue handling in the ART laboratory has previously been
described in detail (Morris et al., 2007). This includes microdis-
persion of the tubule contents, followed by initial examination
and subsequent examinations at 24–48 h.
(A)
(B)
Figure 1 (A) Treatment algorithm. (B) Overall SRR in the prognostic TESA,
therapeutic TESA, and mTESE.
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mTESE procedure
Microdissection testicular sperm extraction is performed
according to Schlegel (Schlegel, 1999). Some patients opted to
receive local anesthesia only but in the majority of cases general
anesthesia is used. Midline incision of the scrotum is made and
carried down to the level of the tunica vaginalis, which is opened
to deliver the testis. Equatorial incision is made and the testis
bivalved. The operating microscope is used to identify plump-
appearing seminiferous tubules, and biopsies are taken from
these areas. These samples are examined by an embryologist in
the operating room after initial gross dispersion by passing the
tissue through a 24 gauge angiocatheter. The procedure is
stopped if spermatozoa are found. If no plump tubules are
found, random biopsies targeting every area of the testis are
taken. If necessary the procedure is carried out on the contralat-
eral testis, as well. Hemostasis is obtained with careful bipolar
cautery, and the tunica albuginea and the tunica vaginalis are
closed with a running 4-0 Vicryl. Standard scrotal closure is per-
formed and gentle pressure dressing is applied.
Statistics and ethics
In patients with more than one prognostic TESA, only the first
TESA was used in data analyses. As the number of therapeutic
TESA/mTESE per prognostic TESA varied, only the initial thera-
peutic procedure was utilized for comparison to avoid skewing
results. Descriptive statistics were performed for the majority of
outcome parameters. Mann–Whitney U-test and Wilcoxon
signed-rank test were used to compare baseline characteristics
of NOA- and OA men, to compare clinical parameters of men
with a successful- or failed TESA and to compare hormonal val-
ues before and after treatment attempts with TESA and mTESE.
Institutional review board approval was obtained for this study.
RESULTS
A total of 208 azoospermic patients, including 126 NOA men
and 82 OA men were included in the study. In 16 cases of anejac-
ulation, azoospermia was diagnosed on at least one SA obtained
through either penile vibratory stimulation or electroejaculation.
In 21 cases, no SA could be obtained and 19 of these were diag-
nosed as OA whereas two were diagnosed as NOA based on the
described criteria. Baseline characteristics of all men are shown
in Table 1 together with etiologies of NOA and OA.
The overall SRR for OA and NOA men on prognostic TESA was
100% (82/82) and 30% (38/125), respectively (Fig. 1B). Thirty-
one OA men proceeded to a therapeutic TESA and spermatozoa
were found in all patients. Eight of the 38 NOA men with a suc-
cessful prognostic TESA chose to proceed to a therapeutic TESA.
One additional NOA man had an initial successful therapeutic
TESA without having a prior prognostic TESA. On a later intracy-
toplasmic sperm injection (ICSI) cycle a second therapeutic
TESA was unsuccessful and he therefore proceeded to
subsequent mTESE cycles with successful outcomes. When
including this additional patient as a success according to the
study methods, the SRR for the therapeutic TESA in NOA men
was 89% (8/9).
Altogether nine NOA men had mTESE after a failed prior TESA
and spermatozoa were found in a single man making the SRR
11% for mTESE. In addition to these nine men, two men decided
not to follow the presented treatment algorithm before having
mTESE; one NOA man underwent a successful mTESE after a
successful prognostic TESA and one OA man opted for a mTESE
after a successful therapeutic TESA with a subsequent failed ICSI
attempt. Table 2 shows SRR in NOA men related to different
clinical parameters. There was no statistical significant differ-
ence in age, pre-TESA testosterone, pre-TESA FSH, testis size,
and BMI (p = 0.5, 0.5, 0.7, 0.7, and 0.3, respectively) between the
NOA men with a successful prognostic TESA and the NOA men
with an unsuccessful prognostic TESA (data now shown). How-
ever, the histological patterns between the NOA men with a suc-
cessful prognostic TESA and the NOA men with an unsuccessful
prognostic TESA was statistically significant different
(p < 0.001). Among NOA men with a successful prognostic TESA
82% had HS, 9% had SCOS, and 9% had MA. Among NOA men
with an unsuccessful prognostic TESA 51% had SCOS, 28% had
Table 1 Baseline data, histology and etiology of NOA and OA patients
Baseline characteristics
NOA (n = 126) OA (n = 82) p
Age at time of
biopsy (years)
34.4  7.2 38.4  8.8 <0.001
Infertility time
(months)
n = 58
30  25
n = 29
34  27
0.5
BMI (kg/m2) n = 90
30.2  8.7
n = 58
28.3  5.8
0.4
Testicular long
axis (cm)
n = 102
3.16  0.97
n = 52
4.56  0.84
<0.001
FSH (mlU/mL) n = 117
18.51  11.60
n = 59
4.60  3.06
<0.001
Testosterone
(ng/mL)
n = 111
3.75  1.68
n = 55
3.92  1.96
0.7
LH (mlU/mL) n = 102
7.93  4.52
n = 46
3.68  2.29
<0.001
PRL (ng/mL) n = 35
9.27  4.73
n = 13
11.02  8.91
0.6
Histology
NOA (n = 79) OA (n = 42)
# MA (%) 18 (23) –
# SCOS (%) 31 (39) –
# HS (%) 29 (37) 12 (29)
# Normal (%) – 30 (71)
# Globally necrotic (%) 1 (1) –
Etiology
NOA (n = 126) OA (n = 82)
58 Idiopathic (46%) 19 Iatrogenic (23%)
20 Cancer therapy (16%)a 19 Anejaeulation (23%)b
13 Cryptorchidism (10%) 14 Vasectomy (17%)
10 Spinal cord injury (8%) 13 CBAVD(16%)
7 AZFc del (6%) 11 Idiopathic (13%)
5 Karyotypec (4%) 4 Ejaculatory duct obstruct (5%)
3 Orchitis (2%) 2 Trauma (3%)
3 Anabolic steroid use (2%) –
3 Klinefelter (2%) –
2 Traumad (2%) –
1 AZFa+b del (1%) –
1 Kallmanns (1%) –
Values are mean  SD unless stated otherwise. aIncluding chemotherapy, bone-
marrow-transplant and radiation. bFor practical reasons men with anejaculation
due to spinal cord injury, diabetic neuropathy and spina bifida were grouped as
OA if they did not fit the described general criteria for NOA. cIncluding 1
46XY,15 ps+, 1 46XY,22pstk-ps, 1 46XY translocation 9qh+, 1 45XY,der(13;14)
(q10;q10) and 1 46XY,t(3;21). dDirect scrotal trauma.
© 2016 American Society of Andrology and European Academy of Andrology Andrology, 2016, 4, 257–262 259
SPERM RETRIEVAL IN AZOOSPERMIC MEN ANDROLOGY
MA, and 21% had HS (data not shown). Pregnancy outcomes are
presented in supplemental Table 1.
Including repeat procedures we performed a total of 267 TESA
on 208 men. Following these 267 TESA we experienced no major
complications with an overall complication rate of 3% (7/267).
Three men experienced a vasovagal syncope during the proce-
dure, three men developed a scrotal hematoma, and one man
developed a spermatic cord hematoma. The four hematomas
were managed by applying scrotal support and administering
NSAID. Following TESA, FSH increased from 24.52  17.52
(mean  SD) to 31.65  15.90 mIU/mL (p = 0.03, n = 12) mea-
sured 29  28 months after TESA, whereas no statistically signif-
icant difference was seen in testosterone levels before
(3.54  1.79 ng/mL) vs. after (4.52  2.19 ng/mL) TESA
(p = 0.24, n = 18) measured 19  25 months after TESA.
Including repeat procedures we performed 14 mTESE with an
overall complication rate of 21% (3/14). One man was unable to
walk because of pain and was treated with IV pain medicine in
the emergency room on day two post-operation. One man devel-
oped scrotal infection and was treated with IV antibiotics and
scrotal abscess drainage. He also developed de novo androgen
deficiency (occurrence of hypogonadism following mTESE that
was not present before mTESE). One man experienced desatura-
tion while in the recovery room, possibly because of aspiration,
and later developed de novo androgen deficiency. Following
mTESE there was a decrease in testosterone from 3.62  1.12 to
2.54  1.29 ng/mL (p = 0.047, n = 7) measured 9  18 months
after mTESE. No statistically significant difference was seen in
FSH levels before (15.57  11.71 mIU/mL) vs. after
(61.23  46.85 mIU/mL) mTESE (p = 0.25, n = 3) measured
18  27 months after mTESE. All patients undergoing TESA or
mTESE recovered fully with the exception of two mTESE sub-
jects who have ongoing hypogonadism requiring testosterone
supplementation.
DISCUSSION
This study evaluates SRR in a prognostic TESA followed by a
decision to proceed with therapeutic TESA or mTESE depending
on individual results. It is one of few studies on sperm retrieval
techniques that incorporate a diagnostic and prognostic
approach before initiating the therapeutic IVF/ICSI cycle with
TESA, cTESE, or mTESE.
Our results indicate that multiple needle-pass TESA is a reli-
able and sufficient sperm retrieval technique when the cause for
azoospermia is obstructive. On other hand, the SRR in the prog-
nostic TESA in NOA men was only 30%. Although this result is in
line with the general literature it is difficult to make direct com-
parisons between studies because of differences in technique
and diversity of the study population. This becomes apparent in
the only published study comparing mTESE and TESA where
TESA was performed with a 23G butterfly needle and 12–18
puncture sites resulting in a SRR of 10% compared with 54% in
mTESE (El-Haggar et al., 2008). The low SRR obtained by TESA
in this study is likely because of the chosen TESA technique. In
general, using a larger needle with multiple passes makes it
possible to aspirate more tissue thus increasing the possibility
of aspirating the patchy distributed spermatozoa as seen in
our study.
The SRR we obtained by mTESE in NOA men, who have failed
a prior prognostic TESA, was disappointing. For comparison,
few other studies have reported outcomes of mTESE after prior
sperm retrieval attempts. In a study by Ramasamy & Schlegel
(2007) the SRR of mTESE in NOA men dropped from 53% in
patients with no prior cTESE to 51% in 1–2 prior cTESE and to
23% in 3–4 prior cTESE and it was concluded that previous tes-
ticular biopsies provide limited or no prognostic value for sperm
retrieval with mTESE. In our study mTESE after a failed TESA
had a SRR of 11% (1/9). In addition to aspirating more tissue in
the method we apply when doing TESA we are also able to sam-
ple the entire testis and the SRR we obtain with mTESE after
failed TESA suggests that our way of performing TESA may be
more predictive of future mTESE results than cTESE. In addition,
although spermatozoa are found in some men after a salvage
mTESE, the SRR drops meaning that some patients are treatable
with less invasive procedures as shown in our study. The chal-
lenge is to find these patients. By using the treatment algorithm
presented in this study, we select the patients who need mTESE.
In this way TESA is an effective first-line treatment and mTESE
should be reserved for patients with a failed TESA. This
decreases the cost of care, as TESA in our center is 400 USD
while the price for mTESE is 6.500 USD.
The use of TESA as a first-line treatment may also have advan-
tages regarding complications after surgical sperm retrieval.
Thus, we found a low rate of self-limiting complications only
with TESA while there were no adverse effects on hormone
Table 2 Subdivision of SRR following prognostic TESA in NOA men
125 NOA mena
BMI (kg/m2) n = 89
BMI ≤ 25 14% (4/28)
25 < BMI ≤ 30 36% (8/22)
30 < BMI ≤ 35 23% (5/22)
BMI > 35 35% (6/17)
Testicular long axis (cm)b n = 101
Size ≤ 3 29% (17/59)
3 < size ≤ 4 22% (6/27)
Size > 4 40% (6/15)
FSH (mIU/mL) n = 116
FSH ≤ 10 23% (7/30)
I0 < FSH ≤ 20 46% (20/44)
20 < FSH ≤ 30 22% (5/23)
FSH > 30 26% (5/19)
Histology n = 79
MA 11% (2/18)
SCOS 7% (2/31)
HS 60% (18/30)
Etiology of NOA n = 125
Idiopathic 22% (13/58)
Cancer treatment 26% (5/19)
Cryptorchidism 69% (9/13)
Spinal cord injury 30% (3/10)
AZF del 29% (2/7)
Karyotype 40% (2/5)
Orchitis 0% (0/3)
Anabolic steroid use 67% (2/3)
Klinefelter 0% (0/3)
Trauma 100% (2/2)
AZFa+b del 0% (0/1)
Kallmanns 0% (0/1)
Failed prior TESE n = 125
No prior TESEc 33% (38/116)
1 prior TESE 0% (0/9)
aOne NOA man not included since he did not have a prognostic TESA. bIf not
bilaterally equal the largest was used for analysis. cOnly biopsies with the purpose
of retrieving sperm are included.
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levels. Meanwhile the complication rate with mTESE was unusu-
ally high. However, it should be kept in mind, that the results are
based on a low number of operations and a learning curve might
affect the complication rate. In addition, the complications after
mTESE may not only be a result of the operation itself but could
stem from repeated procedures on these men as they only had
mTESE performed after failed TESA. Finally, it should be men-
tioned that the use of a large biopsy needle for TESA has previ-
ously produced concerns of injury following multiple passes and
rare testicular bleeding have been reported (Friedler et al., 1997;
Ezeh et al., 1998). However, we did not observe excessive scar-
ring of the testicular tissue when performing mTESE on men
with prior TESA attempts. Thus, studies from more centers are
needed to draw final conclusions on the issue.
In addition to the benefits with sperm retrieval, the low com-
plication rate and the simplicity of the technique, the amount of
tissue we obtain makes our way of performing TESA a good
alternative to cTESE when analysis for histopathology is wanted.
As illustrated in our study, this can aid in making the correct
NOA/OA diagnosis and thereby minimize population bias when
reporting SRR. It also confers an additional advantage because
of the connection between infertility and carcinoma in situ (CIS)
in the testes (Dohle et al., 2012). This connection should be kept
in mind and histopathology, including analysis for CIS, should
be carried out in patients at increased risk of testicular cancer,
that is, patients with cryptorchidism or small atrophic testes
(Dohle et al., 2012).
Histopathology is one among many parameters that have
been suggested as a method to predict outcomes of sperm
retrieval (Glina & Vieira, 2013). However, in a number of stud-
ies on mTESE a biopsy for histology is only obtained during
the surgical sperm retrieval thereby excluding the prognostic
value of histopathological diagnosis (Tsujimura et al., 2002;
Ramasamy et al., 2005; Turunc et al., 2010; Ghalayini et al.,
2011). For example, in a study by Ramasamy et al. (2005)
histopathological diagnosis was known from prior biopsies in
some patients, whereas the other patients had a biopsy taken
during the surgical sperm retrieval. They report an overall SRR
following mTESE of 58%. When looking at their patients with
known histopathology the SRR is 49% (182/372). The drop in
SRR can in theory be because of misdiagnosis of NOA in
patients without histopathological diagnosis or the presence of
less severe histopathological patterns in these patients. Our
criteria for diagnosing NOA were very strict and included
histopathology when available.
Other proposed predictors of sperm retrieval success include
FSH, testosterone, testis size, and inhibin B and although they
provide some prognostic information none of them have been
found to safely predict the success of mTESE or other sperm
retrieval techniques (Glina & Vieira, 2013). The lack of accurate
predictors would encourage the use of a prognostic approach to
avoid unavailability of spermatozoa when ICSI is to be per-
formed on collected oocytes. As a result fine-needle aspiration
(FNA) mapping has been developed to tailor sperm retrieval in
NOA patients (Turek et al., 1997). The technique is performed
with a fine needle and systematically puncturing the testis and
aspirating the tissue in a grid to create a map of where spermato-
zoa are present in the testis. Depending on the number of sites
where spermatozoa are present, the next step is to perform
TESA, cTESE, or mTESE (Beliveau & Turek, 2011). Thus, it is
important to note that FNA mapping is not a sperm retrieval
technique in itself.
Despite the lack of predictors a prognostic approach is rarely
used, as it is argued that the patchy distributed spermatozoa are
hard to find and it would therefore require multiple biopsies
thus increasing the risk of complications (Dabaja & Schlegel,
2013). As a result and because of the relatively high SRR and low
reported complication rates (Schlegel, 1999; Amer et al., 2000;
Okada et al., 2002; Tsujimura et al., 2002; Ramasamy et al.,
2005; Turunc et al., 2010; Ghalayini et al., 2011) many centers
use mTESE as the first choice of retrieving spermatozoa in NOA.
However, this global approach does not allow for individualized
treatment based on the patients needs. The treatment algorithm
presented in this study offers an alternative to mTESE as a first-
line treatment.
To further optimize the algorithm a cryopreservation step after
the prognostic TESA may be implemented. This could be a
method of avoiding cancelled future IVF cycles but the cryosur-
vival of testicular spermatozoa has been questioned (Schlegel,
2009). However, recently the success of freezing testicular sper-
matozoa is increasing (Ohlander et al., 2014) thereby making it
feasible to freeze the sperm retrieved after the prognostic TESA
and use the therapeutic TESA as a backup in case of low post-
thaw cryosurvival.
The main limitation of our study is the low number of patients
proceeding to therapeutic TESA and mTESE, which is mainly
because of the fact that many patients are required to pay the
entire treatment themselves, and therefore choose not to con-
tinue after the prognostic TESA. This observation further high-
lights the need for financial consideration when treating
azoospermic men. Furthermore, our SRR in salvage mTESE lacks
comparison to SRR in mTESE as an initial approach. Thus, fur-
ther studies are needed to investigate this. Regardless we found
a low SRR in salvage mTESE and a good concordance between
prognostic and therapeutic TESA thereby limiting the number of
invasive testicular procedures and cases where spermatozoa are
unavailable for ICSI.
CONCLUSIONS
TESA performed under local anesthesia, in a clinic setting, is a
safe procedure providing reasonable SRR. The success rate of
mTESE drops after a failed TESA indicating that TESA has a role
as a first-line treatment before proceeding to mTESE. Using our
protocol, we are able to give patients more accurate information
on the outcome of their future therapeutic treatment cycle and
design an individual treatment algorithm ensuring that we use
the least invasive sperm retrieval technique possible for any
given patient.
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